Mustang Bio closes $4M public offering of shares and warrants; amends existing warrants

MUSTANG BIO, INC.

Gross proceeds of $4M from offering of shares and warrants at $0.237 per combined unit.
Net proceeds ~$3.3M; potential additional $12M if all series A-1, A-2, A-3 warrants cash-exercised.
Amended 2,588,236 existing warrants from $1.58 to $0.237 exercise price effective May 2.
Offering includes 16.9M shares and three series of warrants each for 16.9M shares.
H.C. Wainwright acted as placement agent; proceeds for working capital.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MUSTANG BIO, INC. amended Warrant Amendment Agreement with the Investor (effective 2024-04-29).

Action: amendment
Counterparty: the Investor
Effective: 2024-04-29

Exact text from the filing

onnection with the Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MUSTANG BIO, INC. entered into Purchase Agreement with a certain institutional investor (effective 2024-04-29).

Action: entry
Agreement: equity purchase
Counterparty: a certain institutional investor
Effective: 2024-04-29

Exact text from the filing

the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”).

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-056459

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.